ClinicalTrials.gg
CompletedNCT03350984Updated Dec 6, 2021Results posted

Insulin Schemes for Type 2 Diabetes Control

A Phase 4 interventional study of NPH insulin and Glargine and Lispro insulin in Type 2 Diabetes Mellitus, sponsored by Universidad de Guanajuato. Completed at 1 site in Mexico. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-12-06.

Sponsored by Universidad de Guanajuato · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing Insulin, Isophane in Diabetes Mellitus, Type 2 — 1 open to participants now, 2 under way, 1 of them phase 3. Insulin, Isophane · Diabetes Mellitus, Type 2.

Enrollment
11th of 17
75 · median 125
Started
2017
the only one that year
Phase 4
5 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
Universidad de Guanajuato

Among the 17 studies testing Insulin, Isophane in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 4, and was the 15th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 17 studies testing Insulin, Isophane in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Isophane

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing Insulin, Isophane in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of the study is to determine differences in glycemic control between a basal-bolus scheme insulin and NPH scheme insulin in a population of hospitalized patients with type 2 diabetes in a Noncritical Care Facility in Mexico. Patients with a recent diagnosis of type 2 and patients on treatment with oral hypoglycaemic agents and insulin or only insulin were included.

The primary outcome of the study is to determine difference in efficacy and security between a basal-bolus scheme insulin and NPH scheme insulin in patients with type 2 diabetes hospitalized in non-critical areas in a hospital in Mexico

Read the detailed description

On the first 4 to 6 h, the use of NPH insulin present a pronounced action peak on the postprandial glucose metabolism, and the rest of its basal action last 12 to 18 h, its cover the postprandial requirements of the first two meals of the day (breakfast and lunch) administering 2/3 of the total dose, and the requirements for the dinner with 1/3 of the total dose at the night. This is considered a good scheme for handling hyperglycemia, and its possible to have less hypoglycemia episodes, which are possible if an ultra-rapid-acting insulin is added and adequate intake is not performed due to multiple factors related to hospitalization.

Today it is uncertain whether there is any clear benefit of using Glargine plus Lantus insulin over NPH insulin in hospitalized patients with type 2 diabetes. Currently, both Glargine and NPH based regimen is practiced in inpatient hospital facilities. Current practice of inpatient insulin regimen is based on the physicians familiarity with a particular insulin type and personal preference rather than evidenced based knowledge. Glargine plus ultrafast insulin are two types of insulin that are more expensive compared to NPH with incidental benefits in hospitalized patients. There are reports in the literature about the incidence of hypoglycemia with this scheme. The current research proposal is to compare these two schemes in the treatment of hospitalized patients with diabetes in a hospital of the second level of care in Mexico.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between 18 and 100 years old.
  • History of type 2 diabetes mellitus (DM2) or that upon admission is diagnosed by values of (HbA1) > 6.5%
  • Fasting central glucose before randomization between 140mg/dl and 400mg/dl
  • Non-critical patients hospitalized in the service of Internal Medicine (MI), General Surgery (CG) and Traumatology (TyO).
  • Patients receiving a diabetic diet orally
  • Treated with diet alone, o any combination of oral anti-diabetic agents or insulin treatment with any dosage before admission.

Exclusion criteria

Exclusion Criteria:

  • Parenteral nutrition
  • Hyperglycemia without a known history of diabetes
  • Impaired renal function ( less than 30)
  • Diabetic ketoacidosis and hyperosmolar state
  • Type 1 Diabetes mellitus
  • Pregnancy
  • Patients on treatment with more than 10mg prednisone or boluses.
  • Known hypopituitarism or adrenal insufficiency
  • Hyperglycaemia due to stress (negative antecedent of DM2, hyperglycemia and HbA1 \<6.5)
  • Severe liver disease ( C score)
  • Acute pancreatitis
  • Patients with sepsis or multiple organ failure
  • Candidates for intensive care unit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    NPH insulin group

    Patients receiving NPH twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they shouldn't receive dose of NPH insulin. Intervention Drug: NPH insulin

    Drug: NPH insulin

  • Active comparator
    Glargine and Lispro insulin group

    Half of the total of Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose will be given as Lispro; doses were divided equally for breakfast, lunch, and dinner. An additional correctional dose of Lispro will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they received glargine once daily and they shouldn't receive doses of lispro. Intervention drug: Glargine and Lispro

    Drug: Glargine and Lispro insulin

Interventions

  • DrugInsulin, IsophaneStudies of Insulin, IsophaneInsulin, Isophane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.

    Also known as: NPH

  • DrugGlargine and Lispro insulin

    Drug pages: Insulin GlargineStudies of Insulin GlargineInsulin Glargine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Insulin LisproStudies of Insulin LisproInsulin Lispro pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.

    Also known as: Glargine and Lispro

06

What researchers measure

Primary outcomes

  1. Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin.

    To determine the differences in the mean daily blood glucose measured in mg/dl, between a basal-bolus scheme and NPH schemes of insulin measured by the mean daily blood glucose.

    Time frame: Fasting blood glucose was taken every day, before breakfast, up to 4 weeks; postprandial glucose was taken every day, 2 hours after breakfast, 2 hours after lunch, and 2 hours after dinner, up to 4 weeks; glucose early morning was taken 3 am, up to 4 week

Secondary outcomes

  1. the Number of Participants With Mild and Severe Hypoglycemic Events

    To measure the number of participants with mild and severe hypoglycemic events

    Time frame: Duration of hospital stay, up to 4 weeks.

  2. Number of Participants With Sustained Glycemic Control During Hospital Stay

    Sustained glycemic control were the number of participants who not had: discharged before sustained control, critical status suspension, death before control, bad attachment to the protocol, interruption due to more than 2 hypoglycemic events during their hospital stay.

    Time frame: blood glucose was taken every day, up to 4 weeks.

07

Results

Posted Jan 18, 2020
Limitations and caveats
Although the patients had an oral diet, the prolonged stay due to complications not associated with DM2 reduced their caloric intake. The physiological scheme is more demanding, making it difficult to stick to the ideal conditions of the study.

Participant flow

A total of 111 hospitalized DM2 patients not critical to the study were evaluated. Of these, 35 did not meet the inclusion criteria and the 75 included participants were randomized into two groups. The recruitment of patients began on November 2, 2017 and ended on June 1, 2018.

Participant flow — Overall Study
MilestoneNPH Insulin GroupGlargine and Lispro Insulin Group
Started3936
Completed3128
Not completed88
Withdrew: Death10
Withdrew: Lost to follow-up56
Withdrew: Protocol violation12
Withdrew: Physician decision10

Outcome measures

PrimaryDifferences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin.

To determine the differences in the mean daily blood glucose measured in mg/dl, between a basal-bolus scheme and NPH schemes of insulin measured by the mean daily blood glucose.

Time frame:
Fasting blood glucose was taken every day, before breakfast, up to 4 weeks; postprandial glucose was taken every day, 2 hours after breakfast, 2 hours after lunch, and 2 hours after dinner, up to 4 weeks; glucose early morning was taken 3 am, up to 4 week
Reported as:
Mean · mg/dl
Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin.
mg/dlNPH Insulin GroupGlargine and Lispro Insulin Group
Fasting blood glucose129.6 ± 23.6135 ± 22.6
Postprandial glucose155.4 ± 29156.2 ± 27.2
Glucose in the early morning127.4 ± 26.6136.2 ± 21.2
Secondarythe Number of Participants With Mild and Severe Hypoglycemic Events

To measure the number of participants with mild and severe hypoglycemic events

Time frame:
Duration of hospital stay, up to 4 weeks.
Reported as:
Count of participants · Participants
the Number of Participants With Mild and Severe Hypoglycemic Events
ParticipantsNPH Insulin GroupGlargine and Lispro Insulin Group
the Number of Participants With Mild and Severe Hypoglycemic Events1515
SecondaryNumber of Participants With Sustained Glycemic Control During Hospital Stay

Sustained glycemic control were the number of participants who not had: discharged before sustained control, critical status suspension, death before control, bad attachment to the protocol, interruption due to more than 2 hypoglycemic events during their hospital stay.

Time frame:
blood glucose was taken every day, up to 4 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Sustained Glycemic Control During Hospital Stay
ParticipantsNPH Insulin GroupGlargine and Lispro Insulin Group
Number of Participants With Sustained Glycemic Control During Hospital Stay3020

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NPH Insulin Group1/39 (2.6%)0/39 (0%)15/39 (38.5%)
Glargine and Lispro Insulin Group1/36 (2.8%)0/36 (0%)11/36 (30.6%)
Most frequent other events
Most frequent other events
EventNPH Insulin GroupGlargine and Lispro Insulin Group
Soft tissue infectionInfections and infestations14/399/36
PneumoniaRespiratory, thoracic and mediastinal disorders0/391/36
Acute renal failureRenal and urinary disorders0/391/36
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/390/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)NPH Insulin GroupGlargine and Lispro Insulin GroupTotal
<=18 years000
Between 18 and 65 years252752
>=65 years14923
Age, Continuous
Age, Continuous(years)NPH Insulin GroupGlargine and Lispro Insulin GroupTotal
Mean59 ± 13.156.4 ± 12.957.8 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)NPH Insulin GroupGlargine and Lispro Insulin GroupTotal
Female202141
Male191534
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NPH Insulin GroupGlargine and Lispro Insulin GroupTotal
Hispanic or Latino393675
Not Hispanic or Latino000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)NPH Insulin GroupGlargine and Lispro Insulin GroupTotal
Mexico393675
Central glucose
Central glucose(mg / dl)NPH Insulin GroupGlargine and Lispro Insulin GroupTotal
Mean237.3 ± 73.1223.1 ± 67230.5 ± 70.2
08

Study locations

1 site
  • Hospital General de León
    León, Guanajuato 37680, Mexico
09

References and documents

Publications

  • Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011 Feb;34(2):256-61. doi: 10.2337/dc10-1407. Epub 2011 Jan 12. PubMed 21228246 ↗
  • Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, Jacobs S, Rizzo M, Peng L, Reyes D, Pinzon I, Fereira ME, Hunt V, Gore A, Toyoshima MT, Fonseca VA. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care. 2013 Aug;36(8):2169-74. doi: 10.2337/dc12-1988. Epub 2013 Feb 22. PubMed 23435159 ↗
  • Christensen MB, Gotfredsen A, Norgaard K. Efficacy of basal-bolus insulin regimens in the inpatient management of non-critically ill patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2885. Epub 2017 Feb 23. PubMed 28067472 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jul 2018, 7 months.

Results were first posted in Jan 2020, 1 year 6 months after primary completion.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 7 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2017
First posted
Nov 22, 2017
StartActual
Nov 2, 2017
Primary completionActual
Jul 1, 2018
CompletionActual
Jul 1, 2018
Results first posted
Jan 18, 2020
Last update
Dec 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03350984
Lead sponsor
Universidad de Guanajuato
Responsible party
Jose Antonio de Jesus Alvarez Canales (PhD, Universidad de Guanajuato) — Principal investigator
First posted
Nov 22, 2017
Start date
Nov 2, 2017
Primary completion
Jul 1, 2018
Completion
Jul 1, 2018
Results posted
Jan 18, 2020
Last update
Dec 6, 2021

Study contacts

Jose A Alvarez, PhD
principal investigator · Universidad de Guanajuato

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Isophane

Start the discussion